Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 13/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | GUSB | P08236 | 1/20 | 0.38 |
| ▸ | CASP6 | P55212 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7650914 | 0.90 | FLT1 (0.40) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL6935413 | 0.83 | CA9 (0.43) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL6937174 | 0.77 | KAT6A (0.46) | KAT6ACA12CA1CA2CA9 | |
| SCHEMBL7648790 | 0.77 | POLB (0.30) | — | |
| SCHEMBL7651605 | 0.73 | CYP1A2 (0.36) | CA12CA1CA2CA9TDP1 | |
| Bromide SCHEMBL6937197 | 0.72 | GAA (0.39) | ALDH1A1MEN1KMT2A | |
| SCHEMBL6940270 | 0.71 | KAT6A (0.44) | KAT6ACA12CA1CA2CA9 | |
| SCHEMBL6937623 | 0.66 | FLT1 (0.43) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL7645895 | 0.64 | BCAT1 (0.39) | KAT6ACA12CA1CA2CA9 | |
| SCHEMBL7652396 | 0.64 | KIF11 (0.31) | SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1125942-B1 | Derivatives of 6-amino or 6-hydrazinosulfonyl-3-quinolyl phosphonic acids, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2003-04-09 | — | — | EP | claimed |
| US-6486143-B2 | NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | LES LABORATOIRES SERVIER (FR) | 2002-11-26 | — | — | US | claimed |
| US-20010031746-A1 | 6-amino- or 6-hydrazino-sulphonyl-3-quinolynyl-phosphonic acid compounds | LES LABORATOIRES SERVIER (FR) | 2001-10-18 | — | — | US | claimed |
| US-6486143-B2 | NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | LES LABORATOIRES SERVIER (FR) | 2002-11-26 | — | — | US | disclosed |
| US-20010031746-A1 | 6-amino- or 6-hydrazino-sulphonyl-3-quinolynyl-phosphonic acid compounds | LES LABORATOIRES SERVIER (FR) | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031746-A1 | 6-amino- or 6-hydrazino-sulphonyl-3-quinolynyl-phosphonic acid compounds | CA6, P2RY6, FPR3 | KAT6A 353/4885CA12 311/4885CA1 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.